Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Mostrar otras versiones (1)

The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Prunas, Ottavia, Warren, Joshua L., Crawford, Forrest W., Gazit, Sivan, Patalon, Tal, Weinberger, Daniel M., Pitzer, Virginia E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722617/
https://www.ncbi.nlm.nih.gov/pubmed/34981074
http://dx.doi.org/10.1101/2021.07.13.21260393
_version_ 1784625549030719488
author Prunas, Ottavia
Warren, Joshua L.
Crawford, Forrest W.
Gazit, Sivan
Patalon, Tal
Weinberger, Daniel M.
Pitzer, Virginia E.
author_facet Prunas, Ottavia
Warren, Joshua L.
Crawford, Forrest W.
Gazit, Sivan
Patalon, Tal
Weinberger, Daniel M.
Pitzer, Virginia E.
author_sort Prunas, Ottavia
collection PubMed
description The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel. We fit two time-to-event models – a mechanistic transmission model and a regression model – to estimate vaccine effectiveness against susceptibility to infection and infectiousness given infection in household settings. Vaccine effectiveness against susceptibility to infection was 80–88%. For breakthrough infections among vaccinated individuals, the vaccine effectiveness against infectiousness was 41–79%. The overall vaccine effectiveness against transmission was 88.5%. Vaccination provides substantial protection against susceptibility to infection and slightly lower protection against infectiousness given infection, thereby reducing transmission of SARS-CoV-2 to household contacts.
format Online
Article
Text
id pubmed-8722617
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-87226172022-01-04 Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel Prunas, Ottavia Warren, Joshua L. Crawford, Forrest W. Gazit, Sivan Patalon, Tal Weinberger, Daniel M. Pitzer, Virginia E. medRxiv Article The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel. We fit two time-to-event models – a mechanistic transmission model and a regression model – to estimate vaccine effectiveness against susceptibility to infection and infectiousness given infection in household settings. Vaccine effectiveness against susceptibility to infection was 80–88%. For breakthrough infections among vaccinated individuals, the vaccine effectiveness against infectiousness was 41–79%. The overall vaccine effectiveness against transmission was 88.5%. Vaccination provides substantial protection against susceptibility to infection and slightly lower protection against infectiousness given infection, thereby reducing transmission of SARS-CoV-2 to household contacts. Cold Spring Harbor Laboratory 2021-12-20 /pmc/articles/PMC8722617/ /pubmed/34981074 http://dx.doi.org/10.1101/2021.07.13.21260393 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Prunas, Ottavia
Warren, Joshua L.
Crawford, Forrest W.
Gazit, Sivan
Patalon, Tal
Weinberger, Daniel M.
Pitzer, Virginia E.
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title_full Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title_fullStr Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title_full_unstemmed Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title_short Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
title_sort vaccination with bnt162b2 reduces transmission of sars-cov-2 to household contacts in israel
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722617/
https://www.ncbi.nlm.nih.gov/pubmed/34981074
http://dx.doi.org/10.1101/2021.07.13.21260393
work_keys_str_mv AT prunasottavia vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT warrenjoshual vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT crawfordforrestw vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT gazitsivan vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT patalontal vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT weinbergerdanielm vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael
AT pitzervirginiae vaccinationwithbnt162b2reducestransmissionofsarscov2tohouseholdcontactsinisrael

Ejemplares similares